- Home
- CDXS vs ARCT Comparison
CDXS vs ARCT Comparison
Compare CDXS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- ARCT
- Stock Information
- Founded
- CDXS 2002
- ARCT 2013
- Country
- CDXS United States
- ARCT United States
- Employees
- CDXS N/A
- ARCT N/A
- Industry
- CDXS Major Chemicals
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- ARCT Health Care
- Exchange
- CDXS Nasdaq
- ARCT Nasdaq
- Market Cap
- CDXS 406.9M
- ARCT 487.0M
- IPO Year
- CDXS 2010
- ARCT N/A
- Fundamental
- Price
- CDXS $5.13
- ARCT $16.41
- Analyst Decision
- CDXS Buy
- ARCT Strong Buy
- Analyst Count
- CDXS 2
- ARCT 7
- Target Price
- CDXS $11.00
- ARCT $65.00
- AVG Volume (30 Days)
- CDXS 739.7K
- ARCT 375.2K
- Earning Date
- CDXS 02-26-2025
- ARCT 03-06-2025
- Dividend Yield
- CDXS N/A
- ARCT N/A
- EPS Growth
- CDXS N/A
- ARCT N/A
- EPS
- CDXS N/A
- ARCT N/A
- Revenue
- CDXS $64,446,000.00
- ARCT $160,399,000.00
- Revenue This Year
- CDXS N/A
- ARCT $7.33
- Revenue Next Year
- CDXS $2.02
- ARCT $4.71
- P/E Ratio
- CDXS N/A
- ARCT N/A
- Revenue Growth
- CDXS N/A
- ARCT N/A
- 52 Week Low
- CDXS $2.53
- ARCT $14.30
- 52 Week High
- CDXS $6.08
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- CDXS 58.39
- ARCT 44.15
- Support Level
- CDXS $4.24
- ARCT $16.07
- Resistance Level
- CDXS $5.51
- ARCT $17.51
- Average True Range (ATR)
- CDXS 0.32
- ARCT 1.36
- MACD
- CDXS 0.00
- ARCT -0.11
- Stochastic Oscillator
- CDXS 82.68
- ARCT 7.62
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.